-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
Tpp2vnXSjCi5/le/uZG0XYGkol8vfETUVCC/1y1npveDIHkR9DiE82yqBhYfzslo
XhEeQwK36KB6pEhCfI5OkQ==
<SEC-DOCUMENT>0001374170-10-000013.txt : 20100426
<SEC-HEADER>0001374170-10-000013.hdr.sgml : 20100426
<ACCEPTANCE-DATETIME>20100426082256
ACCESSION NUMBER: 0001374170-10-000013
CONFORMED SUBMISSION TYPE: SC 13G
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20100426
DATE AS OF CHANGE: 20100426
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0000792977
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 042742593
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-38286
FILM NUMBER: 10768983
BUSINESS ADDRESS:
STREET 1: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02140
BUSINESS PHONE: 6174972070
MAIL ADDRESS:
STREET 1: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02140
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MAGNETICS INC
DATE OF NAME CHANGE: 19920703
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Norges Bank
CENTRAL INDEX KEY: 0001374170
IRS NUMBER: 000000000
STATE OF INCORPORATION: Q8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G
BUSINESS ADDRESS:
STREET 1: BANKPLASSEN2
STREET 2: P.O BOX 1179 SENTRUM
CITY: OSLO
STATE: Q8
ZIP: 0107
BUSINESS PHONE: 004722316922
MAIL ADDRESS:
STREET 1: BANKPLASSEN2
STREET 2: P.O BOX 1179 SENTRUM
CITY: OSLO
STATE: Q8
ZIP: 0107
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13G
<SEQUENCE>1
<FILENAME>efc10-2604_formsc13g.txt
<DESCRIPTION>DISCLOSURE >5%
<TEXT>
UNITED STATES
SECURITIES EXCHANGE COMMISSION
Washington, D.C. 20549
- -------------------------------------------------------------------------------
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
AMAG Pharmaceuticals, Inc.
----------------------------------------------
(Name of Issuer)
Common Stock, par value USD 0.01 per share
-----------------------------------------------------
(Title of Class of Securities)
00163U106
---------------------
(CUSIP Number)
April 19, 2010
----------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Continued on following pages
Page 1 of 5 Pages
<PAGE>
SCHEDULE 13G
CUSIP No.: 00163U106 Page 2 of 5 Pages
.................................................................................
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
NORGES BANK (THE CENTRAL BANK OF NORWAY)
.................................................................................
2. Check the Appropriate Box if a Member of a Group
(a) [ ]
(b) [ ] N/A
.................................................................................
3. SEC Use Only
.................................................................................
4. Citizenship or Place of Organization
NORWAY
.................................................................................
Number of 5. Sole Voting Power 1,085,460
Shares
Beneficially ................................................................
Owned by Each
Reporting 6. Shared Voting Power 0
Person With ................................................................
7. Sole Dispositive Power 94,210
................................................................
8. Shared Dispositive Power 991,250
.................................................................................
9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,085,460
.................................................................................
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions)
N/A
.................................................................................
11. Percent of Class Represented by Amount in Row (9)
5.17% based on 20,987,794 issued Common Stock
.................................................................................
12. Type of Reporting Person:
OO
<PAGE>
CUSIP No.: 00163U106 Page 3 of 5 Pages
Item 1(a). Name of Issuer:
AMAG Pharmaceuticals, Inc. (the "Issuer").
Item 1(b). Address of Issuer's Principal Executive Offices:
100 Hayden Avenue
Lexington, MA 02421
United States of America
Item 2(a). Name of Person Filing:
This Statement is filed on behalf of each of the following
persons (collectively, the "Reporting Persons"):
NORGES BANK (CENTRAL BANK OF NORWAY)
Item 2(b). Address of Principal Business Office or, if None, Residence:
Bankplassen 2
PO Box 1179 Sentrum
NO 0107 Oslo
Norway
Item 2(c). Citizenship:
Norwegian
Item 2(d). Title of Class of Securities:
Common Stock, par value USD 0.01 per share
Item 2(e). CUSIP Number:
00163U106
Item 3. If This Statement is Filed Pursuant to ss.ss.240.13d-1(b) or
240.13d-2(b) or (c),
Check Whether the Person Filing is a:
This Item 3 is not applicable.
Item 4. Ownership:
Item 4(a) Amount Beneficially Owned
As of April 19, 2010, Norges Bank may be deemed to be the
beneficial owner of 1,085,460 Common shares.
Item 4(b) Percent of Class:
The number of Shares which Norges Bank may be deemed to be the
beneficial owner constitutes approximately 5.17% of the total
number of Common Stock in issue.
<PAGE>
Page 4 of 5 Pages
Item 4(c) Number of Shares of which such person has:
NORGES BANK (CENTRAL BANK OF NORWAY)
(i) Sole power to vote or direct the vote: 1,085,460
(ii) Shared power to vote or direct the vote: 0
(iii) Sole power to dispose or direct the disposition of: 94,210
(iv) Shared power to dispose or direct the disposition of: 991,250
Item 5. Ownership of Five Percent or Less of a Class:
This Item 5 is not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another
Person:
This Item 6 is not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding
Company:
This Item 7 is not applicable.
Item 8. Identification and Classification of Members of the Group:
This Item 8 is not applicable.
Item 9. Notice of Dissolution of Group:
This Item 9 is not applicable.
Item 10. Certification:
By signing below each of the Reporting Persons certifies that,
to the best of their knowledge and belief, the securities referred to above were
not acquired and are not held for the purpose of or with the effect of changing
or influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction
having that purpose or effect.
<PAGE>
Page 5 of 5 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
NORGES BANK
Date: April 26, 2010
By: /s/ Jonas Lexmark
----------------------
Name: Jonas Lexmark
Title: Analyst
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----